Company: HCTI
Filing Date: 2025-09-02
Form Type: 8-K/A
Source: 0001213900-25-082708
Chunk: 1

Company: Healthcare Triangle, Inc.
Filing Date: 2025-09-02
Form: 8-K/A
Chunk 1
---
2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

<div align='center'>Explanatory Note</div>

The Company is filing this Amendment to: (i) report
Amendment No. 1 to the Agreement described in the Original Report and (ii) include the financial statements and pro forma financial information
required by Item 9.01(a) and (b) of Form 8-K. Except as set forth herein, this Amendment does not amend or update any other information
in the Original Report.

<div align='center'>1</div>

Item 1.01 Entry into a Material Definitive Agreement.

On August 28, 2025, the Company and Niyama Healthcare,
Inc. entered into Amendment No. 1 to their Asset Transfer Agreement dated June 16, 2025. Amendment No. 1 replaces Clause (ii) of Section
1(b) of the Agreement to provide that the Seller will receive 1,388,041 restricted shares of the Company’s common stock, issuable
on the effective date after receiving approval of such issuance by a majority of the voting power of the Company’s voting stock.
The amendment reflects the Company’s 1-for-249 reverse stock split and otherwise leaves the Agreement in full force and effect.
The foregoing summary is qualified in its entirety by the text of Amendment No. 1 to Asset Transfer Agreement, filed as an exhibit to
this Amendment as Exhibit 10.1, and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(a) Financial statements of businesses acquired.

The audited balance sheet of Niyama as of December
31, 2024 and 2023 and the audited statements of operations, changes in stockholder’ equity, and cash flows for the years ended December
31, 2024 and 2023, and the related notes thereto, are filed herewith and attached hereto as Exhibit 99.1, and are incorporated herein
by reference.

The audited balance sheet of Ezovion as of December
31, 2024 and 2023 and the audited statements of operations, changes